June 15 (Reuters) - Spyre Therapeutics ( SYRE ) said on

Monday its experimental bowel disease drug met the main goal of

significantly reducing disease severity in a mid-stage trial.

Here are some details:

* The company is testing the drug, SPY002, in patients with

moderate-to-severe ulcerative colitis that causes long-lasting

ulcers and inflammation in the digestive tract.

* The drug significantly reduced disease severity as

measured by a microscopic scoring system that assesses

inflammation and tissue damage in the colon - cutting scores by

10.7 points after 12 weeks of treatment, the company said.

* Secondary results showed 33% of patients achieved clinical

remission, while 42% showed improvement on endoscopy, meaning

the colon looked less inflamed when examined with a camera.

* SPY002 is an experimental antibody designed to last longer

in the body and target TL1A, a protein that drives inflammation

and tissue damage in inflammatory bowel disease.

* The study involved patients who had long-standing disease,

with an average duration of about seven years, and more than a

third had previously received advanced treatments.

* SPY002 was well tolerated, with a safety profile

consistent with other drugs targeting TL1A, Spyre added.

* The most common side effects were joint pain, high blood

pressure, nausea, ulcerative colitis flare-ups, and viral

respiratory infections.

* The trial is a two-part mid-stage study testing three

experimental drugs - SPY001, SPY002 and SPY003 - alone and in

combinations in patients with moderate-to-severe ulcerative

colitis.

(Reporting by Siddhi Mahatole in Bengaluru)